Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.

Autor: Iglesias P; Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda (Majadahonda), Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), Calle Manuel de Falla 1, 28222, Madrid, Spain. piglo65@gmail.com., Biagetti B; Department of Endocrinology, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Araujo-Castro M; Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain., Alcázar V; Department of Endocrinology, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain., Guerrero-Pérez F; Department of Endocrinology, Hospital Universitari de Bellvitge (L'Hospitalet de Llobregat), Barcelona, Spain., Rivero N; Department of Endocrinology, Complexo Hospitalario Universitario de A Coruña and Universidad de A Coruña, A Coruña, Spain., Casteràs A; Department of Endocrinology, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Gómez CG; Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda (Majadahonda), Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), Calle Manuel de Falla 1, 28222, Madrid, Spain., Izquierdo BG; Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda (Majadahonda), Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), Calle Manuel de Falla 1, 28222, Madrid, Spain., Torres VV; Departamento de Endocrinología y Nutrición, Hospital Universitario de Getafe, Getafe, Madrid, Spain., Pascual-Corrales E; Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain., Pavón I; Departamento de Endocrinología y Nutrición, Hospital Universitario de Getafe, Getafe, Madrid, Spain., Villabona C; Department of Endocrinology, Hospital Universitari de Bellvitge (L'Hospitalet de Llobregat), Barcelona, Spain., Cordido F; Department of Endocrinology, Complexo Hospitalario Universitario de A Coruña and Universidad de A Coruña, A Coruña, Spain., Díez JJ; Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda (Majadahonda), Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), Calle Manuel de Falla 1, 28222, Madrid, Spain.; Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Jazyk: angličtina
Zdroj: Journal of neuro-oncology [J Neurooncol] 2022 Nov; Vol. 160 (2), pp. 351-359. Date of Electronic Publication: 2022 Nov 10.
DOI: 10.1007/s11060-022-04149-7
Abstrakt: Background: In recent years, dopamine agonists (DAs) have become an attractive therapeutic option to prevent both tumor growth and post-surgical tumor remnant growth in clinically non-functioning pituitary adenoma (NFPA).
Aim: To analyze our experience on the effect of cabergoline (CAB) on tumor remnant after initial surgery in NFPA patients.
Patients and Methods: A retrospective and multicenter study of NFPA patients with tumor remnant after surgery treated with CAB was performed.
Results: From a total of 142 NFPA patients (79 men, 55.2%; mean age 57.2 ± 14.2 year) who underwent surgery, we selected 62/142 (43.7%) patients (32 men, 51.6%; mean age 59.3 ± 13.9 year) with tumor persistence (TP) after surgery. In 22/62 (35.5%) TP patients CAB was used (CAB group), while the rest of the patients (40/62, 64.5%) underwent active surveillance [observation (OBS) group)]. The maximum diameter of the tumor remnant did not change significantly in either the CAB group [11.5 (6.0-16.9) mm vs. 12.0 (7.0-15.0) mm, p = 0.85) or the OBS group [8.5 (6.0-13.7) mm vs. 9.0 (6.2-14.0) mm, p = 0.064) at the end of the follow-up [13 (10.5-17) vs. 77.5 (50.2-107.2) months, CAB vs. OBS group; p < 0.001]. At the end of the treatment period with CAB most of the patients (n = 20/22, 90.9%) showed no progression of the tumor remnant [stable disease, SD (n = 17/22, 77.2%) and partial response, PR (n = 3/22, 13.6%)], while 2/22 patients (9.1%) exhibited progression. Similar response rates were observed in the OBS group [SD (n = 32/40, 80%), PR (n = 2/40, 5%), and progression (n = 6/40, 15%)]. Although no statistically significant differences (p = 0.42) were found in these responses, the percentage of progression was 1.65 times higher in the OBS group compared to the CAB group. On the contrary, the percentage of PR was 2.72 times higher in the CAB group compared to the OBS group, despite a significantly shorter follow-up period in the CAB group.
Conclusion: Although the present study showed no significant differences in the type of tumor response between the CAB and OBS groups of patients, the percentage of PR was higher and that of progression lower in the CAB group compared to the OBS group. This finding does not rule out a potential therapeutic benefit of CAB in the management of tumor remnant in patients with NFPA undergoing surgery.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: